Q-omics provides the consensus-scored RPS15AP25 profile across patient tissues and cancer cell-line models. RPS15AP25 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RPS15AP25 is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, RPS15AP25 RNA expression shows 9,848 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, LUSC, and LSCC as cancer lineages where RPS15AP25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS15AP25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS15AP25 survival associations across molecular data types. RPS15AP25 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS15AP25 RNA expression–survival associations across cancer types. High RPS15AP25 expression shows unfavorable associations in KICH, THCA, OV and UVM, but favorable associations in HNSC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .017). Together, the overview and detailed table identify HNSC as the clearest survival context for RPS15AP25 RNA expression.
This table summarizes RPS15AP25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS15AP25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS15AP25 shows lower tumor expression in LUSC and KICH and higher tumor expression in KIRC. The LUSC box plot shows higher RPS15AP25 RNA expression in normal versus tumor tissue (log2 FC = −0.073, t-test p = .005).
This table shows molecular features associated with RPS15AP25 in patient tissues and cancer cell lines. In patient samples, RPS15AP25 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
